Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Signs Option Deal for MD Anderson Brain Cancer Test

NEW YORK (GenomeWeb News) – Houston-based startup Castle Biosciences has signed an option agreement to license a biomarker-based brain cancer test from the University of Texas MD Anderson Cancer Center.
 
The firm said that the test, which was developed and validated at MD Anderson in collaboration with other US institutions, could potentially predict a patient’s likelihood to respond to standard treatment based on the cancer’s genetic footprint. It said that it would provide more details on the test in the near future.
 
Further details of the agreement were not disclosed.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.